Role of Antireflux Mucosal Ablation in the Management of Gastroesophageal Reflux Disease: Case Closed or Is the Jury Still Out?

Antireflux mucosal ablation (ARMA) has emerged as a novel endoscopic therapy for gastroesophageal reflux disease (GERD), aiming to augment the gastroesophageal junction through mucosal scarring. However, recent randomized controlled trials (RCTs) have reported conflicting results, raising questions regarding its true clinical utility. In this news and views, we will discuss two recently published RCTs analyzing the efficacy and safety of ARMA in the management of GERD.